Meeting
2024 ASCO Breakthrough
Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study.
Authors
Minji Uh
Loxo@Lilly, Indianapolis, IN
Minji Uh , Maurice Perol , Koichi Goto , Benjamin J. Solomon , Keunchil Park , Ernest Nadal , Emilio Bria , Claudio Martin , Jair Bar , Justin Williams , Tarun Puri , Jian Li , Boris K. Lin , Caicun Zhou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Thoracic Cancers,Breast Cancer,Gynecologic Cancer,Head and Neck Cancer,Hematologic Malignancies,Genetics/Genomics/Multiomics,Healthtech Innovations,Models of Care and Care Delivery,Viral-Mediated Malignancies,Other Malignancies or Topics
Sub Track
Advanced Disease
Clinical Trial Registration Number
NCT04194944
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 199)
DOI
10.1200/JCO.2024.42.23_suppl.199
Abstract #
199
Poster Bd #
J4
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
First Author: Martin Reck
Poster
2022 ASCO Annual Meeting
A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.
First Author: Marina Chiara Garassino
Poster
2020 ASCO Virtual Scientific Program
Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC).
First Author: Delvys Rodriguez-Abreu
Poster
2020 ASCO Virtual Scientific Program
Nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated efficacy and safety results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455).
First Author: Christian Grohé